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ABSTRACT
Introduction: Risk-reducing-salpingo-oophorectomy (RRSO) inevitably leads BRCA mutation carriers to 
premature menopause.
Areas covered: To evaluate the existing evidence for use of postmenopausal hormone therapy (HT) in 
BRCAmc, after RRSO or menopause occurring naturally, for both breast cancer (BC) survivors and those 
without BC.
Expert opinion: All BC survivors are excluded from any HT treatment: in other BRCAmc, before 51 years 
of age the benefits of HT overcome the risks after RRSO and/or premature ovarian insufficiency (POF). 
After 51 years of age, it is important to treat only women with important vasomotor symptoms, after 
the failure of alternative therapies. Estrogens-only therapy plays a key role in hysterectomized women 
(HW). In the case of an intact uterus (UW), associations with the lowest dose of progestins/natural 
progesterone derivatives have to be preferred, as progestins has been shown to play an important role 
in BC transformation, especially in BRCA1mc. No studies have been performed in BRCAmc with regard 
to ‘progestin-free’ HT, in particular the old tibolone (both in HW and UW) and the new tissue-selective 
estrogen complex (in UW). However, preliminary data obtained from the general population are 
reassuring about the use of these ‘progestin-free’ preparations and BC safety.
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Patients carrying germline mutations in BRCA1 or 2 genes 
present a life-long increased risk of developing ovarian and 
breast cancer. In particular, patients with BRCA1 mutations 
have a 72% lifetime risk of breast cancer (BC) and 44% of 
ovarian cancer (OC), while the same risk in patients with 
BRCA2 mutations is 69% and 17%, respectively [1].
Performing risk-reducing-salpingo-oophorectomy (RRSO) 
for these patients seems to be the best strategy to reduce 
the risk of OC by up to 96%: it has also been shown to 
reduce the risk of BC by up to 50% [2], though this protec-
tive effect has recently been widely questioned [3]. 
According to the National Comprehensive Cancer Network 
(NCCN) guidelines, RRSO is recommended for BRCA1 muta-
tion carriers between the ages of 35 and 40, or when child 
bearing is complete. The option of delaying RRSO until age 
40–45 in women with BRCA2 mutations may be considered 
as there appears to be a later average age of onset 
(approximately 8–10 years) than in women with a BRCA1 
mutation [4]. However, RRSO inevitably leads patients to 
premature menopause compared with the average general 
age of menopause in women (51 years). This involves a num-
ber of side effects related to estrogen deprivation, being 
divided into acute and long-term symptoms. Acute symp-
toms include hot flushes, insomnia, arthralgia, irritability, 
a decline in libido, and genitourinary syndrome, while long- 
term symptoms comprehend an increase in cardiovascular 
risk, dementia, and early-onset osteoporosis [5]. For these 
reasons, it is important to offer these patients the possibility 
of postmenopausal hormone therapy (HT), if no contraindi-
cations exist (mainly a previous occurrence of BC), to limit 
the systemic effects related to early estrogen depletion 
associated with iatrogenic menopause and to protect them 
from long-term side effects. Nonetheless, it is mandatory 
not to forget the increased risk of BC development typically 
associated with this group of patients, which could be 
further increased by the use of exogenous hormones. 
Moreover, some of these women opt for bilateral risk- 
reducing mastectomy (BRRM) instead of surveillance to 
further reduce BC risk, although the efficacy of this practice 
has recently been questioned especially for BRCA2 mutation 
carriers [6].
Recently, we have discussed the possible use of combined 
hormonal contraceptives to avoid unintended pregnancies in 
these women [7]: in this Meta-opinion, we aim to evaluate the 
existing evidence for the other side of the coin, the systemic 
postmenopausal HT.
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2. Body
Nowadays, possible postmenopausal HTs can be divided into 
typical HT formulations [estrogens (E)-only and combined oes-
tro-progestin (EP) HT] or ‘progestin-free’ HT, with different 
ways of administration, hormonal components, and regimens 
(Table 1).
2.1. Typical E and EP treatments
In general, E-only HT is for hysterectomized women, while EP 
HT is generally offered to women with an intact uterus 
(Table 1).
Rebbeck et al. published a prospective cohort study in 2005 
including a sample of 462 BRCA1 and 2 mutation carriers 
undergoing RRSO, for which the subsequent risk of BC was 
assessed in relation to the intake of HT. Results showed that, 
for a median follow-up of 3.6 years, the use of HT (both E and 
EP combinations) did not influence the protective effect of 
RRSO on subsequent BC risk [Hazard Ratio: 0.37 (95% CI 0.-
14–0.96)] [8]. This was also confirmed by another retrospective 
study published by Gabriel et al. in 2009 which considered the 
risk of BC in a sample of 73 BRCA1 and 2 mutation carriers 
undergoing RRSO (and in some cases concomitant prophylac-
tic hysterectomy), of which n = 33 have subsequently started 
HT (with E, EP or not specified) (median length of HT use: 
2.8 years) [9]. It was found that only 3/33 (9.1%) women 
developed BC in the group of patients undergoing HT, in 
comparison to 9/29 (31.0%) patients in the group without 
HT. In particular, all BC cases in the HT group came from the 
group of patients undergoing E-only treatments, not from the 
EP group [9]. In contrast, a milestone study concerning HT, 
published by Anderson et al. in 2012 about the Women’s 
Health Initiative (WHI) randomized study data, considered 
the risk of BC in hysterectomized postmenopausal patients 
of the general population undergoing therapeutic regimen 
with equine conjugated estrogen (CE) (E-group) in comparison 
to placebo. This was the first study showing that CE use alone 
reduces the risk of BC [Hazard Ratio: 0.77 (95% CI 0.62–0.95)] 
while, on the contrary, highlighting the role of progestins 
in BC carcinogenesis, with a Hazard Ratio in the EP group of 
1.25 (95% CI 1.07–1.46) in comparison to placebo [10]. This 
figure had already been demonstrated for BRCA1 mutation 
carriers. Notably, a matched case–control study performed 
by Eisen et al. in 2008 [11] on 472 BRCA1 mutation carrier 
postmenopausal women (iatrogenic or not) had been con-
ducted to examine whether the use of HT (E and EP combina-
tions) was associated with a risk of BC. Similarly to [10], they 
found an inverse correlation between the risk of BC and the 
use of E-only HT. In this study, the characteristics of hormonal 
receptors in BCs [Estrogen Receptors (ERs), Progesterone 
Receptors (PRs)] were also considered in patients undergoing 
RRSO and subsequent HT. HT use was reported for 12% of 
patients with ER-positive tumors and for 23% of patients with 
ER-negative tumors (p = 0.29), confirming the correlation 
between triple negative cancers and BRCA1 gene mutations, 
despite the use of HT [11]. Conversely, in BRCA2 mutation 
carriers, BC cases are more frequently ER+ and PR+ [12].
Finally, a recent prospective cohort study published by 
Kotsopoulos et al. in 2018 [13] considered the risk of BC over 
time in a sample of 872 BRCA1 mutation carrier women under-
going RRSO (mean follow up: 7.6 years), of which only 377 
started E-only or EP HT. Overall, HT use after RRSO was not 
associated with an increased risk of BC. However, once again, 
a different incidence of BC was found in the two groups with 
different HT treatments. In particular, women undergoing 
E-only HT showed a lower risk than those submitted to EP 
therapeutic regimens (12% vs. 22%; absolute difference: 10%; 
log rank p = 0.04). For women who underwent RRSO prior to 
45 years of age, each year of E-only HT use was associated 
with a significant 18% reduction in BC risk (95% CI 0.69–0.97), 
whereas each year of EP HT was associated with 
a nonsignificant 14% increase in BC risk (95% CI 0.90–1.46). 
The potential adverse effect of progestin-containing HT on BC 
is in line with the emerging role of the PR activation of the 
nuclear factor κB (RANK)-signaling pathway in BRCA1 BC 
development [13]. Considering this issue, especially in BRCA1 
mutation carriers, the doses of progestins used in HT should 
be limited, choosing compositions that associate the lowest 
doses of E with the lowest doses of progestins/natural proges-
terone derivatives. Only if there is a need to increase the doses 
of E due to ineffectiveness of HT on symptoms, health-care 
providers should think about increasing the doses of the 
progestin components from low to moderate and high doses 
(Table 2).
Unfortunately, the use of E-only HTs is not allowed in 
patients with an intact uterus, as estrogenic stimulation of 
the endometrium without progesterone/progestin-induced 
inhibition increases the risk of endometrial hyperplasia and 
endometrial cancer (Table 1). For this reason, BRCA1 mutation 
carriers should consider the removal of the uterus to avoid the 
use of progestin-containing HT at the time of RRSO. Moreover, 
although the overall risk for uterine cancer after RRSO was not 
increased, the risk of serous endometrial carcinoma was 
reported to be increased in BRCA1 women [14]. Other advan-
tages of hysterectomy during RRSO included eliminating the 
small risk of tamoxifen (TAM)-induced endometrial cancer 
in BC subjects and avoiding the possible, although never 
clearly reported, tubal carcinogenesis in the uterine interstitial 
cornua. However, a hysterectomy at the time of RRSO slightly 
Table 1. Different ways of administration, hormonal components, and regimens 
of typical and ‘progestin-free’ hormone therapy (HT) formulations currently 
available in Italy today, in relation to possible women users. CE: conjugated 
estrogen. BZA: bazedoxifene.
‘Typical’ HT Possible women users
Estrogen-only (E-only) 
Transdermal (patch, gel): estradiol 
Oral: estradiol valerate
Hysterectomized women
Oestro-progestins (EP) (sequential, 
combined, continue, cyclic) 
Transdermal (patch): estradiol + 
levonorgestrel or norethisterone acetate 
Oral: estradiol or estradiol valerate + 
nomegestrol acetate, drospirenone, 
dydrogesterone, norethisterone acetate, 
cyproterone acetate, medroxyprogesterone 
acetate, dienogest
Women with an intact uterus
‘Progestin-free’ HT
Tibolone 2.5 mg/day Hysterectomized and women 
with an intact uterus
CE (0.45 mg) and BZA (20 mg) Women with an intact uterus
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increases surgical risks and short-term morbidity. 
Hysterectomy should be considered as an optional part of 
prophylactic surgery for BRCA mutation carriers, and the deci-
sion of whether to perform it should be on the basis of correct 
personalized counseling on the basis of individual factors, 
associated uterine diseases, and the patient’s wishes, espe-
cially in BC survivors [15].
2.2. ‘Progestin-free’ treatments
In addition to the classic HT regimens, characterized by the 
administration of E-only or EP combinations, there are also 
other therapeutic alternatives, in particular tibolone (T) (avail-
able since 1988) and a new TSEC (Tissue Selective Estrogen 
Complex), composed of CE and bazedoxifene (BZA), a selective 
modulator of estrogen receptors (SERM, Selective Estrogen 
Receptor Modulator) (available since 2014). However, in rela-
tion to these other types of ‘progestin-free’ HT, we do not 
have specific studies specifically performed in the BRCA muta-
tion carrier setting.
T is a synthetic steroid whose metabolite activities are 
partly estrogenic, partly androgenic and partly progester-
one-like, depending on the tissue in which they act, 
approved for therapy in both hysterectomized women and 
those with an intact uterus (Table 1). In particular, T inhibits 
the enzyme sulphatase, which reduces the desolfatation of 
estrone (E3) sulfate and blocks cell proliferation in the 
breast, stimulating apoptosis [16]. T was associated with 
the least breast epithelial proliferation (evaluated by prolif-
erating cell nuclear antigen immunohistochemistry), but 
also the least apoptosis (by caspase-3 immunohistochemis-
try) in comparison to other EP treatments [17]. Several 
studies have also shown a reduction in breast density dur-
ing T treatment, in contrast with ‘typical’ E-only or EP HTs 
[18,19]. The Million Women Study in 2003 showed that the 
magnitude of BC risk during HT was substantially greater for 
EP than for T or E-only treatments in the general population 
[20]. When we consider the risk of OC in the general popu-
lation undergoing T therapy, the results are controversial: 
a study performed in Denmark showed an increased 
Relative Risk of 1.42 (95% CI 1.01–2.00) [mainly serous can-
cer with a Relative Risk of 2.21 (95% CI 1.48–3.32)] in 
comparison to those who had never used T therapy [21]. 
This result was disproved by another case–control study 
conducted in Finland in 2013 that considered the risk of 
OC in patients undergoing various types of HT formulations, 
showing that the use of T did not significantly increase the 
risk of OC in contrast to other EP regimens [Odds Ratio for 
>1 year of use: 1.01 (95% CI 0.64–1.60)], especially in 
a sequential scheme [22]. However, this effect should not 
be important after RRSO in BRCA mutation carriers, as it is 
not the case for the other possible HTs [8,9,11,13]. On the 
other hand, T use may increase the risk of endometrial 
cancer [21].
The pharmacological association between CE (0.45 mg) 
and BZA (20 mg) has been recently approved as HT only in 
women with an intact uterus (Table 1). The peculiarity of 
this formulation is the presence of BZA, a molecule belong-
ing to the class of SERM, like another well-known protective 
molecule used in oncology (TAM). It is able to act as an 
E agonist or antagonist in different tissues. In particular, this 
molecule has an E agonist action in the bone tissue, while it 
acts as an E antagonist in both breast and endometrial 
tissue, reducing the risk of BC, endometrial hyperplasia 
and endometrial cancer [23,24]. Several preclinical studies 
have shown a reduction in breast and endometrial cell 
proliferation during TSEC treatment in both mice and 
some primates [25,26], and TSEC has demonstrated 
a direct antiproliferative effect on human BC cells [27]. Its 
clinical studies are reassuring with regard to its safety on 
breast tissue. The ‘Selective estrogens, Menopause, And 
Response to Therapy’ (SMART) 1, a multicentre double- 
blind study involving 3,397 menopausal women from the 
general population treated with CE/BZA at different dosages 
(CE 0.45 mg/BZA 20 mg or CE 0.625 mg/BZA 20 mg) or 
placebo for 2 years, showed that the incidence of BC 
between the different treatment groups was similar (0.4% 
for CE 0.45 mg/BZA 20 mg; 0% for CE 0.625 mg/BZA 20 mg, 
0.2% for placebo) [28]. Moreover, the 1-year subgroup of 
the SMART 5 trial [29] compared BZA 20 mg plus CE 0.45 or 
0.625 mg, placebo, BZA 20 mg, and CE (0.45 mg) plus 
medroxyprogesterone acetate (MPA) (1.5 mg) in 940 
women from the general population with technically accep-
table digital mammograms at screening and at 1 year. TSEC 
demonstrated noninferiority to placebo in breast density 
modification. Mammographic breast density decreased 
from baseline with TSEC, while the EP HT combination 
tested (CE+MPA) significantly increased breast density from 
baseline in comparison to placebo. No clinical data about 
OC risk during TSEC treatment are presently available, but 
this effect should not be important after RRSO in BRCA 
mutation carriers.
3. Expert opinion
It is reasonable to think that HT might be safely prescribed in 
postmenopausal BRCA mutation carriers with different thera-
peutic opportunities, although there is currently an important 
Table 2. Low dose or moderate to high dose progestin components currently 
available in Italy for oestro-progestin EP hormone therapy (HT), ordered by the 








100 mg 200 mg
Dydrogesterone 5 mg 10 mg
Nomegestrol Acetate 2.2 mg 5 mg
Medroxyprogesterone 
acetate
5 mg 10–20 mg
Testosterone 
Derivatives
Norethisterone acetate 0.1 mg 0.5–2.5 mg
Levonorgestrel 0.75 mg –
Intrauterine 
levonorgestrel
Intrauterine systems releasing 8, 9 
or 20 µg daily.
–
Dienogest 2 mg –
Spironolactone 
Derivatives
Drospirenone 2 mg –
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skepticism in the general population, and often also still in 
many clinicians, both gynecologists, breast surgeons, and 
oncologists. The benefits of HT are linked to the prevention 
of cardiovascular risk, dementia, and early onset of osteoporo-
sis associated with the estrogen depletion. This is particularly 
important when menopause arises suddenly (iatrogenic 
menopause) and at an earlier age of the ‘physiological’ 
event, as in the case of BRCA mutation carriers who are sub-
jected to early RRSO according to NCCN guidelines [4]. With 
regard to BRCA mutation carriers who are facing spontaneous 
menopause at a ‘physiological’ age (51 years old), HT should 
only be considered in cases where the woman exhibits highly 
disabling vasomotor symptoms. Other therapeutic evidence- 
based non-hormonal possibilities are available for women 
with mild symptoms [selective serotonin reuptake inhibitors 
(SSRI), SSRI/serotonin–norepinephrine reuptake inhibitor 
(SNRI) low-dose, clonidine, gabapentin, pregabalin, phytooes-
trogens]. It is also important to know that all BRCA mutation 
carriers with a personal history of BC are excluded from the 
possibility of any HT, as numerous studies have shown that HT 
use is related to the recurrence of BC [30].
The possible scenarios of BRCA mutation carriers unaf-
fected by BC needing HT are reported in Figure 1. In gen-
eral, before 51 years of age, the benefits of HT overcome 
the risks after RRSO and/or premature ovarian insufficiency 
(POF). After 51 years of age, it is important to treat only 
women with important vasomotor symptoms, after the fail-
ure of alternative therapies, with a carefully shared evalua-
tion of the benefits/risks ratio, especially in the case of RRSO 
refusal (HT can potentially increase the risk of both OC 
and BC), after detailed counseling to the women.
Among the therapeutic alternatives for BRCA mutation 
carriers, E-only therapy plays a key role in hysterectomized 
women. In the case of an intact uterus, associations with low- 
dose progestins/natural progesterone derivatives have to be 
preferred, as progestins has been shown to play an important 
role in BC transformation, especially in BRCA1 mutation 
carriers.
Presently, no studies have been performed in the population 
of BRCA mutation carriers with regard to ‘progestin-free’ HT, in 
particular the old T and the new TSEC. However, preliminary data 
obtained from the general population are reassuring about the 
use of these ‘progestin-free’ preparations and BC safety. 
Considering the good safety profile on both breast (better than 
EP HT combined regimens) and ovarian tissue, T can be 
a reasonably valid therapeutic alternative in this population, 
both in hysterectomized women and women with an intact 
uterus. TSEC, due to the role of E antagonism on breast tissue 
linked to BZA similarly to TAM, could be another interesting 
option in women with an intact uterus. Nevertheless, well- 
conducted studies about their use and safety as HT after RRSO 
in BRCA mutation carriers are urgently needed.
Among limitations, the next studies have to clarify the role of HT 
in BRCA mutation carriers who have already undergone BRRM, 
because these patients have been excluded from the larger studies 
considered in this review [8,11,13]. Furthermore, we have not 
considered the possible use of modern topical or oral hormonal 
treatments for genitourinary syndrome, such as promestriene, 
estriol, estradiol, prasterone, and ospemifene, especially in BC 
survivors.
To conclude, the interest in safe HT preparations for BRCA 
mutation carriers, for both BC survivors and those unaffected 
by BC, must be heavily funded and encouraged to improve 
their quality of life, to limit the oncological risk and to prevent 
the long-term side effects of menopause after RRSO or occur-
ring physiologically.
Figure 1. Possible scenarios of HT treatment in BRCA mutation carriers during the reproductive lifespan in relation to RRSO, previous breast cancer and age of 
menopause occurrence. CE: conjugated estrogen.
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